Eef Schimmelpennink, LENZ Therapeutics CEO
April 3, 2024 11:30 AM EDTUpdated 12:35 PM
R&D

LENZ plans NDA sub­mis­sion for pres­by­opia eye drops this year, looks to launch in 2025

Katherine Lewin

News Reporter

LENZ Ther­a­peu­tics plans to seek FDA ap­proval for its in­ves­ti­ga­tion­al eye drops for pres­by­opia, set­ting up the drug to com­pete against Ab­b­Vie’s Vuity and Ora­sis …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times